The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group.
Sook Hee Hong
No relevant relationships to disclose
Jae Ho Byun
No relevant relationships to disclose
Soohyeon Lee
No relevant relationships to disclose
Hoon-Gu Kim
No relevant relationships to disclose
Hyo Jin Lee
No relevant relationships to disclose
Kyung Hae Jung
No relevant relationships to disclose
Sang-Cheol Lee
No relevant relationships to disclose
Na-Ri Lee
No relevant relationships to disclose
Jina Yun
No relevant relationships to disclose
Dae-Sik Hong
No relevant relationships to disclose
In Sook Woo
No relevant relationships to disclose
Kyong Hwa Park
No relevant relationships to disclose
Sun Young Rha
No relevant relationships to disclose